The main objective of this study was to evaluate the safety of second-line pemetrexed in Stage IIIB or IV NSCLC.
Overall, 95 patients received pemetrexed 500 mg/m2 i.v. over Day 1 of a 21-day cycle. Patients also received oral dexamethasone, oral folic acid and i.m. vitamin B12 supplementation to reduce toxicity. NCI CTC 2.0 was used to… (More)